Volume 26, Issue 3 (September 2022)                   Physiol Pharmacol 2022, 26(3): 239-247 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Akhavan Rasoolzadeh E, Nazarali P, Alizadeh R. Effect of endurance and resistance training on adropin and insulin resistance among overweight men: a randomized clinical trial. Physiol Pharmacol 2022; 26 (3) :239-247
URL: http://ppj.phypha.ir/article-1-1786-en.html
Abstract:   (1603 Views)
Introduction: Insulin resistance and low adropin level are two risk factors for comorbidity in overweight individuals. The aim of this study was to investigate whether eight weeks of endurance (ET) and resistance training (RT) could affect adropin and insulin resistance among overweight men. Methods: In this clinical trial, 27 overweight university students (20-28 years of age; 25
29.9) were recruited and randomly allocated into three groups: control (n=9), RT (n=9) and ET (n=9). The RT consisted of eight moves (3 sessions/ week) performed in two sets of 6 repetitions with 30% of 1 repetition maximum (RM) during week 1, and gradually increased to four sets of 6 repetitions with 70% of 1RM by the 8th week. The ET program included treadmill running (3 days/ week) performed during 15-40min for eight weeks with an intensity of 50-80% of the maximum heart rate. Results: The results showed that the levels of adropin in the ET group significantly increased more than that of RT and control group. Moreover, fasting blood insulin and homeostasis model assessment of insulin resistance significantly decreased in both groups, while fasting blood glucose and quantitative insulin-sensitivity check index did not significantly change. Conclusion: It is concluded from the results of this study that eight weeks of ET and RT could help improve the metabolic profile among overweight youngsters. It is also possible that ET is more beneficial in this matter than RT.
Full-Text [PDF 817 kb]   (277 Downloads)    

References
1. (WHO) WHO. 2020. 'Obesity and overweight', Accessed 10/22/2020. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
2. Akcilar R, Kocak F, Simsek H, Akcilar A, Bayat Z, Ece E, et al. Antidiabetic and hypolipidemic effects of adropinin streoptozotocin-induced type 2 diabetic rats. Bratisl Lek Listy 2016; 117: 100. [DOI:10.4149/BLL_2016_020]
3. Alizadeh R, Golestani N, Moradi L, Rezaeinejad N. Effect of aerobic exercise with maximal fat oxidation intensity, on adropin and insulin resistance among overweight women. Iranian Journal of Endocrinology and Metabolism 2018; 20: 81-88.
4. Beckers PJ, Denollet J, Possemiers NM, Wuyts FL, Vrints CJ, Conraads VM. Combined endurance-resistance training vs. endurance training in patients with chronic heart failure: a prospective randomized study. Eur Heart J 2008; 29: 1858-1866. [DOI:10.1093/eurheartj/ehn222]
5. Chen R M, Yuan X, Ouyang Q, Lin X Q, Ai Z Z, Zhang Y, et al. Adropin and glucagon-like peptide-2 are associated with glucose metabolism in obese children. World J Pediatr 2019; 15: 565-571. [DOI:10.1007/s12519-019-00296-6]
6. Dengel DR, Pratley RE, Hagberg JM, Rogus EM, Goldberg AP. Distinct effects of aerobic exercise training and weight loss on glucose homeostasis in obese sedentary men. J Appl Physiol 1996; 81: 318-325. [DOI:10.1152/jappl.1996.81.1.318]
7. Despres JP, Pouliot MC, Moorjani S, Nadeau A, Tremblay A, Lupien P, et al. Loss of abdominal fat and metabolic response to exercise training in obese women. Am J Physiol Endocrinol Metab 1991; 261: 159-167. [DOI:10.1152/ajpendo.1991.261.2.E159]
8. Esteghamati A, Ashraf H, Khalilzadeh O, Zandieh A, Nakhjavani M, Rashidi A, et al. Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007). Nutr Metab 2010; 7: 26-26. [DOI:10.1186/1743-7075-7-26]
9. Fujie S, Hasegawa N, Kurihara T, Sanada K, Hamaoka T, Iemitsu M. Association between aerobic exercise training effects of serum adropin level, arterial stiffness, and adiposity in obese elderly adults. Appl Physiol Nutr Metab 2017; 42: 8-14. [DOI:10.1139/apnm-2016- 0310]
10. Gao S, Ghoshal S, Zhang L, Stevens JR, McCommis KS, Finck BN, et al. The peptide hormone adropin regulates signal transduction pathways controlling hepatic glucose metabolism in a mouse model of diet-induced obesity. J Biol Chem 2019; 294: 13366-13377. [DOI:10.1074/jbc.RA119.008967]
11. Gao S, McMillan RP, Jacas J, Zhu Q, Li X, Kumar GK, et al. Regulation of substrate oxidation preferences in muscle by the peptide hormone adropin. Diabetes 2014; 63: 3242-3252. [DOI:10.2337/db14-0388]
12. Greenberg A, McDaniel M. Identifying the links between obesity, insulin resistance and β‐cell function: potential role of adipocyte‐derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 2002; 32: 24-34. [DOI:10.1046/j.1365-2362.32.s3.4.x]
13. Gu X, Li H, Zhu X, Gu H, Chen J, Wang L, et al. Inverse correlation between plasma adropin and ET-1 levels in essential hypertension: A cross-sectional study. Medicine 2015; 94. [DOI:10.1097/MD.0000000000001712]
14. Hall J E. 2010. Guyton and Hall textbook of medical physiology e-Book (Elsevier Health Sciences).
15. Hansen E, Landstad BJ, Gundersen KT, Torjesen PA, Svebak S. Insulin sensitivity after maximal and endurance resistance training. J Strength Cond Res 2012; 26: 327-334. [DOI:10.1519/JSC.0b013e318220e70f]
16. Jasaszwili M, Billert M, Strowski MZ, Nowak KW, Skrzypski M. Adropin as A Fat-Burning Hormone with Multiple Functions-Review of a Decade of Research. Molecules 2020; 25: 549. [DOI:10.3390/molecules25030549]
17. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106: 473-481. [DOI:10.1172/JCI10842]
18. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-2410. [DOI:10.1210/jcem.85.7.6661]
19. Kirwan JP, Kohrt WM, Wojta DM, Bourey RE, Holloszy JO. Endurance exercise training reduces glucose-stimulated insulin levels in 60-to 70-year-old men and women. J. Gerontol 1993; 48: 84-90. [DOI:10.1093/geronj/48.3.M84]
20. Kopelman P. Health risks associated with overweight and obesity. Obes Rev 2007; 8: 13-17. [DOI:10.1111/j.1467-789X.2007.00311.x]
21. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults: the National Health and Nutrition Examination Surveys, 1960 to 1991. Jama 1994; 272: 205-211. [DOI:10.1001/jama.1994.03520030047027]
22. Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab 2008; 8: 468-481. [DOI:10.1016/j.cmet.2008.10.011]
23. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419. [DOI:10.1007/BF00280883]
24. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. Jama 2003; 289: 76-79. [DOI:10.1001/jama.289.1.76]
25. Nishida Y, Tokuyama K, Nagasaka S, Higaki Y, Shirai Y, Kiyonaga A, et al. Effect of moderate exercise training on peripheral glucose effectiveness, insulin sensitivity, and endogenous glucose production in healthy humans estimated by a two-compartment-labeled minimal model. Diabetes 2004; 53: 315-320. [DOI:10.2337/diabetes.53.2.315]
26. Otten J, Ahrén B, Olsson T. Surrogate measures of insulin sensitivity vs the hyperinsulinaemiceuglycaemic clamp: a meta-analysis. Diabetologia 2014. [DOI:10.1007/s00125-014- 3285-x]
27. Poehlman ET, Dvorak RV, DeNino WF, Brochu M, Ades PA. Effects of resistance training and endurance training on insulin sensitivity in nonobese, young women: a controlled randomized trial. J Clin Endocrinol Metab 2000; 85: 2463-2468. [DOI:10.1210/jcem.85.7.6692]
28. Rice B, Janssen I, Hudson R, Ross R. Effects of aerobic or resistance exercise and/or diet on glucose tolerance and plasma insulin levels in obese men. Diabetes Care 1999; 22: 684-691. [DOI:10.2337/diacare.22.5.684]
29. Rudvik A, Månsson M. Evaluation of surrogate measures of insulin sensitivity - correlation with gold standard is not enough. BMC Med Res Methodol 2018; 18: 64-64. [DOI:10.1186/s12874-018-0521-y]
30. Ryan AS, Nicklas BJ. Reductions in plasma cytokine levels with weight loss improve insulin sensitivity in overweight and obese postmenopausal women. Diabetes Care 2004; 27: 1699- 1705. [DOI:10.2337/diacare.27.7.1699]
31. Sanchis-Gomar F, Alis R, Rampinini E, Bosio A, Ferioli D, La Torre A, et al. Adropin and apelin fluctuations throughout a season in professional soccer players: Are they related with performance? Peptides 2015; 70: 32-36. [DOI:10.1016/j.peptides.2015.05.001]
32. Thapa D, Xie B, Manning JR, Zhang M, Stoner MW, Huckestein BR, et al. Adropin reduces blood glucose levels in mice by limiting hepatic glucose production. Physiol Rep 2019; 7. [DOI:10.14814/phy2.14043]
33. Wong C-M, Wang Y, Lee JTH, Huang Z, Wu D, Xu A, et al. Adropin is a brain membranebound protein regulating physical activity via the NB-3/Notch signaling pathway in mice. J Biol Chem 2014; 289: 25976-25986. [DOI:10.1074/jbc.M114.576058]
34. Yosaee S, Khodadost M, Esteghamati A, Speakman J R, Shidfar F, Nazari M N, et al. Metabolic syndrome patients have lower levels of adropin when compared with healthy overweight/obese and lean subjects. Am J Mens Health 2017; 11: 426-434. [DOI:10.1177/1557988316664074]
35. Yosaee S, Soltani S, Sekhavati E, Jazayeri S. Adropin-a novel biomarker of heart disease: a systematic review article. Iran J Public Health 2016; 45: 1568.

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.